FDA Grants Fast Track Designation to CS-1103 for Fentanyl Overdose Reversal
核心洞察
The FDA has granted Fast Track designation to CS-1103, a first-in-class small molecule developed by Clear Scientific for treating acute fentanyl intoxication.
CS-1103 works by binding and encapsulating intoxicants in the blood to rapidly reverse toxic effects and accelerate clearance into urine.
The injectable therapeutic demonstrated safety and tolerability in Phase 1 trials, with Phase 2 trials for fentanyl expected to begin in June 2026.
Clear Scientific Inc. (搜索) announced that the U.S. Food and Drug Administration has granted Fast Track designation to CS-1103, a first-in-class small molecule therapeutic for treating acute fentanyl intoxication. The designation facilitates development and expedites review of medicines that demonstrate potential to treat serious conditions and fill unmet medical needs.
Novel Mechanism of Action
CS-1103 represents a new therapeutic approach for opioid overdose (搜索) management. In non-clinical studies, the injectable therapeutic binds and encapsulates intoxicants in the blood, rapidly reversing their toxic effects. Following this initial action, CS-1103 accelerates the clearance of intoxicants into urine, preventing further harm to patients.
The drug has completed Phase 1 clinical trials, where it was shown to be safe and well tolerated in humans at clinically relevant doses. Clear Scientific expects to initiate Phase 2 trials for fentanyl in June 2026.
Addressing Treatment Gaps
"There are substantial gaps in current overdose and detox treatments for opioids," said Shekar Shetty, CEO of Clear Scientific. "Based on non-clinical studies, CS-1103, administered alongside naloxone, can greatly increase the safety of acute intoxication scenarios, by preventing renarcotization."
The therapeutic also shows promise for improving transitions to addiction treatment. According to Shetty, CS-1103 "has the potential to improve rapid and safe transition to addiction treatments, particularly buprenorphine, through its ability to remove virtually all the opioids from the body in a short period of time."
Clinical Significance in Opioid Crisis
The Fast Track designation comes as the opioid crisis continues to devastate communities nationwide. Opioids cause 2,500 emergency department visits and 150 deaths daily in the United States. In 2024, synthetic opioids were associated with more than 55,000 fatalities, and according to the White House, the fentanyl-fueled opioid crisis cost the U.S. economy nearly $2.7 trillion in 2023, impacting healthcare, criminal justice, and productivity across all communities.
Company Background and Development
Clear Scientific was co-founded in March 2019 by Professor George M. Whitesides of Harvard University, utilizing technology licensed from Massachusetts General Hospital and the University of Maryland. The company is pioneering a new treatment paradigm for conditions involving excess compounds in the body by developing highly selective, small molecule sequestrants that bind, inactivate, and rapidly clear these compounds.
The company receives funding from the National Institute on Drug Abuse of the National Institutes of Health under award number UG3DA059286 and collaborates with a network of medical and academic professionals in its research efforts.